摘要
目的通过生物信息学高通量多组学数据库分析浸润性乳腺癌组织中prohibitin(PHB)的表达及其临床意义。方法下载TCGA和METABRIC乳腺癌数据,应用多种工具比较癌组织和癌旁组织中PHB表达情况,并分析PHB表达与乳腺癌患者临床病理特征及预后之间的相关性,进行PHB蛋白互相作用预测及功能分析。结果 PHB在多种癌组织中较癌旁组织高表达,乳腺癌中PHB基因突变和表达量改变比例较高;PHB基因表达对于乳腺癌具有良好的诊断效能(P<0.01);PHB表达与乳腺癌患者ER受体、HER2、PAM50分型、肿瘤纯度等指标有关(P<0.05)。生存分析表明,乳腺癌PHB高表达是影响乳腺癌的独立危险因素(P<0.01)。HRAS、KSR1、ARAF与PHB相互作用且相关性较高,在乳腺癌组织中可见表达改变。结论 PHB在乳腺癌、卵巢癌等多种癌组织中表达升高,并且PHB高表达明显影响乳腺癌患者预后,PHB基因表达对乳腺癌的诊断效能较好,可作为乳腺癌诊断、预后的潜在标志物。
Objective To analyze the expression and clinical significance of prohibitin(PHB) in invasive breast cancer(BC) based on high throughput multi-omics databases. Methods The breast cancer data were downloaded from TCGA and METABRIC databases, and the expressions of PHB in BC tissues and adjacent normal tissues were compared by various bioinformatics tools. The correlations of PHB expression with clinicopathological features and prognosis of BC patients were analyzed, and the interaction and function of PHB protein were predicted. Results Compared with adjacent normal tissues, PHB was highly expressed in many kinds of cancer tissues, especially in invasive breast cancer where the gene mutation and expression changes of PHB had higher proportion. The expression level of PHB had good diagnostic efficacy for BC(P<0.01). The expression level of PHB was significantly correlated with the expressions of ER and HER2, PAM50 typing and tumor purity of BC patients(P<0.05). The survival analysis showed that the high expression of PHB was an independent risk factor of BC(P<0.01). HRAS, KSR1 and ARAF interacted with PHB, with significant correlation. The changed expressions of HRAS, KSR1 and ARAF could be found in BC tissues. Conclusion The expression of PHB increases in various cancer tissues such as breast cancer, ovarian cancer and so on. The high expression of PHB has significant influence on the prognosis of BC patients. The expression of PHB has good diagnostic efficacy for BC, which may be used as a potential marker for the diagnosis and prognosis of BC.
引文
[1]Sun YS, Zhao Z, Yang ZN, et al. Risk factors and preventions of breast cancer[J]. Int J Biol Sci, 2017, 13(11): 1387-1397.
[2]Peng YT, Chen P, Ouyang RY, et al. Multifaceted role of prohibitin in cell survival and apoptosis[J]. Apoptosis, 2015, 20(9): 1135-1149.
[3]Thuaud F, Ribeiro N, Nebigil CG, et al. Prohibitin ligands in cell death and survival: mode of action and therapeutic potential[J]. Chem Biol, 2013, 20(3): 316-331.
[4]Wang K, Long B, Zhou LY, et al. CARL lncRNA inhibits anoxia-induced mitochondrial fission and apoptosis in cardiomyocytes by impairing miR-539-dependent PHB2 downregulation[J]. Nature Communications, 2014, 5: 3596.
[5]Merkwirth C, Dargazanli S, Tatsuta T, et al. Prohibitins control cell proliferation and apoptosis by regulating OPA1-dependent cristae morphogenesis in mitochondria[J]. Genes Dev, 2008, 22(4): 476-488.
[6]Chen YW, Chou HC, Lyu PC, et al. Mitochondrial proteomics analysis of tumorigenic and metastatic breast cancer markers[J]. Funct Integr Genomics, 2011, 11(2): 225-239.
[7]He Q, Zhang SQ, Chu YL, et al. Separation and identification of differentially expressed nuclear matrix proteins in breast carcinoma forming[J]. Acta Oncologica, 2010, 49(1): 76-84.
[8]Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses[J]. Nucleic Acids Res, 2017, 45(W1): W98-W102.
[9]Vasaikar S, Straub P, Wang J, et al. LinkedOmics: analyzing multi-omics data within and across 32 cancer types[J]. Nucleic Acids Research, 2018, 46(D1): D956-D963.
[10]孙海燕,杜欣娜,樊伟平,等.基于高通量多组学数据分析ESYT3在乳腺癌中的表达及临床意义[J].临床检验杂志,2018,36(8):579-582.
[11]Szklarczyk D, Morris JH, Cook H, et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible[J]. Nucleic Acids Res, 2017, 45(D1): D362-D368.
[12]Li S, Balmain A, Counter CM. A model for RAS mutation patterns in cancers: finding the sweet spot[J].Nat Rev Cancer, 2018, 18(12): 767-777.
[13]Zhou L, Lyons-Rimmer J, Ammoun S, et al. The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors[J]. Oncogene, 2016, 35(26): 3443-3453.
[14]Mercer K, Giblett S, Oakden A, et al. A-Raf and Raf-1 work together to influence transient ERK phosphorylation and Gl/S cell cycle progression[J]. Oncogene, 2005, 24(33): 5207-5217.
